Key Takeaways from the PARADIGM Study

Video

Drs Gupta and Makkar conclude their discussion by highlighting key takeaways from the PARADIGM study and future directions that may address unmet needs in the field of la/mUC.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Recent Videos
      Adjuvant Durvalumab Yields Improved Efficacy in NIAGARA Regimen
      Adjuvant Durvalumab Yields Improved Efficacy in NIAGARA Regimen
      Durvalumab/Chemotherapy Deserving of Consideration in Neoadjuvant MIBC
      Durvalumab/Chemotherapy Deserving of Consideration in Neoadjuvant MIBC
      Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
      Enfortumab Vedotin Combo Supersedes Other Advanced Bladder Cancer Options
      Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
      EV-302 Trial Shows ‘Impressive’ Data in Bladder Cancer Responder Population
      Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
      Managing AEs Associated With The EV-302 Trial Regimen in Bladder Cancer
      Updated findings from the phase 3 EV-302 trial show enduring responses and survival improvements with enfortumab vedotin plus pembrolizumab.
      Enfortumab Vedotin Combo Yields ‘Transformative’ Urothelial Cancer Outcomes
      Utilizing a Multidisciplinary Team Approach to Bladder Cancer Treatment
      Utilizing a Multidisciplinary Team Approach to Bladder Cancer Treatment
      AEs to Monitor With Enfortumab Vedotin/Pembrolizumab in Advanced Bladder Cancer
      AEs to Monitor With Enfortumab Vedotin/Pembrolizumab in Advanced Bladder Cancer
      Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
      Recap: Bladder Cancer Treatment Algorithm
      Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
      Bladder Cancer: Treatment in the Metastatic Setting
      Related Content
      Antihistamines Added to IO Associated with Longer Survival in Urothelial Carcinoma

      Antihistamines Added to IO Associated with Longer Survival in Urothelial Carcinoma

      Tim Cortese
      March 4th 2025
      Article

      Retrospective analyses found that antihistamines added to atezolizumab yielded a 46% OS rate, a 48% CSS rate, and a 23% PFS rate in patients with metastatic urothelial carcinoma.

      NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

      NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
      March 4th 2025
      Podcast

      The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

      Durable Responses in Low-Grade, Intermediate-Risk NMIBC with UGN-102

      Durable Responses in Low-Grade, Intermediate-Risk NMIBC with UGN-102

      Ashling Wahner
      February 15th 2025
      Article

      Data from the ENVISION and ATLAS trials demonstrated clinically meaningful responses with UGN-102 in the treatment of low-grade, intermediate-risk NMIBC.

      Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

      Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

      Matthew Fowler;Jun Gong, MD
      March 15th 2022
      Podcast

      Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

      The safety profile of dato-DXd in the phase 1 TROPION-PanTumor01 trial is comparable with prior reports of the agent.

      Dato-DXd Yields Encouraging Activity in Pretreated Advanced Bladder Cancer

      Russ Conroy
      February 15th 2025
      Article

      The safety profile of dato-DXd in the phase 1 TROPION-PanTumor01 trial is comparable with prior reports of the agent.

      Avelumab Maintenance Extends Survival in Advanced Urothelial Carcinoma, Regardless of Diabetes

      Avelumab Maintenance Extends Survival in Advanced Urothelial Carcinoma, Regardless of Diabetes

      Jax DiEugenio
      February 14th 2025
      Article

      Avelumab maintenance demonstrated improved survival outcomes in advanced urothelial carcinoma, including patients with diabetes, in the JAVELIN Bladder 100 study.